

18-19 November | Virtual
22 November | Milan



EUROPEAN PHARMACOVIGILANCE CONGRESS 2024

The **European Pharmacovigilance Congress**, organized by **Pharma Education Center**, is recognized as one of the most important and appreciated **global pharmacovigilance conferences**.

EUPV congress is proud to have **high quality scientific content** as its main characteristic which has attracted growing interest from speakers, sponsors and **participants from all over the world**.

The EUPV congress gathers **PV professionals** at all career levels, including **key decision makers** (e.g. VPs, Executives and Directors,) interested in the always evolving pharmacovigilance world and its new trends, since they are always looking for new ideas to implement more efficient and effective strategies and tools for their departments.


To further improve the value of the congress and continuously make it more and more interesting by bringing new ideas and scientific contents, this year the **Scientific Advisory Group** has been further widened with the addition of new PV key opinion leaders who need no introduction since their knowledge and skills are world class.

EUPV congress is the forum where all **PV stakeholders from all over the world** meet and exchange ideas.

EUPV Congress 2023 IN NUMBERS

EUPV 2023 - AUDIENCE

VP/Ceo/Director/
Head/QPPV



Officer/specialist/
Manager

380 ATTENDEES representing



120 COMPANIES



5 CONTINENTS



50 COUNTRIES



Delegates' feedback 2023 edition

- Extremely knowledgeable speakers and good variety of "topics".
- Very well-organized event. Excellent speakers and vast knowledge sharing forum.
- I loved the panel discussions following presentations, many relevant issues were addressed. One of the best conferences I attended!
- It was superb. Thank you for everything.

CONFERENCE FORMAT

- 18-19 November | Virtual 9 am - 6 pm
- 21 November | APERITIF TIME, NH Milano Congress Centre 6-9 pm
- 22 November | Face to face, NH Milano Congress Centre 9.30 am - 5 pm

APERITIF TIME - November 21 from 6 to 9 pm

NH Milano Congress Centre

Reserve your place to meet and network with your with experts and opinion leaders



This year the congress will include:

- *25 Topics*
- *11 Virtual & face to face parallel sessions*
- *25 Interactives round tables*
- *2 Face to face workshops*
- *2 LECTIO Magistralis*

Our speakers are from: regulatory agencies, international pharmacovigilance organizations, patients' organizations, industry, academia. The intense, scientific interaction between speakers and delegates is a further invaluable plus of the event.

FEATURED TOPICS.... in progress

Day 18- virtual

- BIOLOGICAL BASIS OF ADVERSE REACTIONS WITH FOCUS ON SCARS
- IMMUNOLOGICAL ADVERSE REACTIONS
- SIGNAL DETECTION
- RISK MANAGEMENT
- COMMUNICATING SAFETY INFORMATION IN THE DIGITAL ERA

Day 19 - virtual

- AUTHORITIES' ASSESSMENT OF PV INFORMATIONS
- REAL WORD DATA & REAL WORD EVIDENCE
- MANUFACTURING & PV INTERFACES
- DRUG SAFETY IN MARKETING AUTHORIZATION APPLICATIONS
- EVOLVING LANDSCAPE OF ELECTRONIC SAFETY DATA IN PV
- NON-EU PV REQUIREMENTS

Day 22 - Milan

- EVOLVING PHARMACOVIGILANCE STRATEGIES
- MAIN GLOBAL AND LOCAL PV UPDATES
- PRACTICAL EXPERIENCE OF APPLYING ARTIFICIAL INTELLIGENCE IN PV
- AUDIT & INSPECTIONS

and more parallel sessions coming ...



NEW VENUE!

NH MILANO CONGRESS CENTRE



Plenary Room: up to 400 attendees
Parallel Room: up to 100 attendees



- 5 minutes walking distance from Assago Forum Metro Stop
- Close to the highway exit
- 30 minutes by car from Linate airport, Duomo Cathedral and Milan Central Station

SCIENTIFIC ADVISORY GROUP



Andrew Bate
Vp Safety Innovation & Analytics |
GSK



Giovanni Furlan
Worldwide Safety Site Lead - Thessa-
loniki (Greece), Safety Risk Lead,
Director | Pfizer S.r.l.



Glyn Belcher
CEO of PV Consultancy Ltd



Calin A. Lungu
DDCS S.A., CEO



Mattia Calissano
Head of Pharmacovigilance |
Orchard Therapeutics



Hrvoje Maček
VP, Medical & Scientific Affairs, EU
QPPV | PrimeVigilance



Gian Nicola Castiglione
Director Global Pharmacovigi-
lance | Chiesi Farmaceutici



Valentina Mancini
Senior Director Pharmacovigilance
QPPV | Shionogi Europe



Mircea Ciuca
Global Therapeutic Area Head in
Global Clinical Safety and Pharma-
covigilance



Jan Petracek
CEO, iVigee, Director, Institute of
Pharmacovigilance



Marco Sardella
Chief Pharmacovigilance Officer &
EU-UK QPPV | ADIENNE Pharma &
Biotech



CONFIRMED SPEAKERS



Mayssa AbouGhannam

Country Safety Team Lead, Saudi Arabia, Gulf, Pakistan, Afghanistan | Janssen



Roxana Dondera

Head of Pharmacovigilance and Risk Management Unit | National Agency for Medicine and Medical Devices of Romania



Fazil Afzal

Medical Assessor | Medicines and Healthcare products Regulatory Agency (MHRA)



Iva Galic

Pharmacovigilance Inspector Expert-HALMED



Klaudija Marijanovic Barac

Sr. Director, EU&UK QPPV deputy, Head Periodic Reports and Risk Management Centre | TEVA



Ilaria Grisoni

Exec. Dir., Head of EU/International PV & Office of QPPV, EEA QPPV | Jazz Pharmaceuticals



Andrew Bate

Vp Safety Innovation & Analytics | GSK



Terenzio Ignoni

SVP Quality and CMC at Gain Therapeutics



Glyn Belcher

CEO of PV Consultancy Ltd



Vibha Jawa

Executive Director | Bristol Myers Squibb



John - Joseph Borg

Director Post-Licensing | Malta Medicines Authority



Calin A. Lungu

DDCS S.A., CEO



Margherita D'Antuono

EU-UK QPPV | Piramal Critical Care



Arduino Mangoni

Strategic Professor in Clinical Pharmacology | Flinders University, Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia



Anne De Groot

CEO/CSO and Director | EpiVax



Zeljana Margan Koletic

Senior Manager, Risk Management Plans (RMP) Team Leader | Teva



CONFIRMED SPEAKERS



Robert Massouh
Head of (PV) Risk Management
and Benefit Risk Evaluation | Gsk



Sofia Trantza
Senior pharmacovigilance expert,
PRAC member Greece



Nicholas Moore
Emeritus Professor of clinical phar-
macology | University of Bordeaux



Chia Yu Chu
Prof. Department of Dermatology |
National Taiwan University



Iva Novak
Head of European Pharmacovigi-
lance and EU QPPV | Teva



Maria Beatrice Panico
Principal Consultant | Scendea



Georgios Papazisis
Professor of Clinical Pharmacology;
Medical Director, Clinical Research
Unit, School of Medicine, Aristotle
University of Thessaloniki



Lembit Rago
Secretary-General | Council for
International Organizations of
Medical Sciences (CIOMS)



Amy Roseberg
Senior Director and Consultant,
Immunology | EpiVax, Inc



Geeta Shanbhag
VP Pharmacovigilance and
Medico - Regulatory Affairs | Ipca
laboratories Ltd



EUPV CONGRESS SAGE AWARD

On November 22, in Milan, the EUPV CONGRESS SAGE AWARD 2024 will be presented to the author/s of the article published in 2024 in the SAGE Journal "Therapeutic Advances in Drug Safety" (Impact Factor: 4,4) that has been judged as being most noteworthy to be presented at a pharmacovigilance congress.

The article will be selected by the Scientific Board and SAGE among those that have been downloaded more times.



EUPV 2024 Booklet

All abstracts of the congress presentations will be published under an Open Access license. Therefore, they can be read online and downloaded at no cost.

MEDIA PARTNERS

Published by SAGE, Therapeutic Advances in Drug Safety (Impact Factor: 4,4) is an international peer-reviewed Open Access journal, delivering the highest quality original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in drug safety, providing an online forum for rapid dissemination of recent research and perspectives in this area. As the official Media Partner of the 6th edition of the European Pharmacovigilance Congress, Therapeutic Advances in Drug Safety will be publishing an online abstract supplement which will be free to access online.

For more info:

Website: <https://journals.sagepub.com/home/taw>

E-mail: jonathan.collin@sagepub.co.uk

Twitter: @TADrugSafety





ENTRY FEES

	Face to Face November 22	Virtual November 18-19	Virtual + Face to Face November 18-19 November 22	
Early bird	400 €	600 €	750 €	Deadline October 18
Full price	500 €	650 €	950 €	

VAT not included

Hospitals, universities and freelance professionals get a 40 % discount to be applied to published prices

Discounts are not cumulative

For multiple registrations contact:
info@pharmaeducationcenter.it

TEL (+39) 055 7224179
(+39) 055 7224076
FAX (+39) 055 7227014

REGISTER HERE

For further information and/or further assistance please contact (+39) 055 7224179 or email: amministrazione@pharmaeducationcenter.it

EVENT CANCELLATION

If the minimum number of participants is not reached, Pharma Education Center reserves the right to cancel or schedule the event for another date. Formal communication will be given within 5 days before the event date. In this case Pharma Education Center will refund the registration fee in full and without additional charges. Alternatively, the participant can request a spendable coupon for participating in another PEC event scheduled in the current year.

CANCELLATION TERMS

In order to cancel enrolment to a event, please email info@pharmaeducationcenter.it within 2 weeks before the starting date of the event. Once this term will be expired, the entire fee will be charged.

ATTENDEE REPLACEMENT

It is possible to replace a participant with another without additional costs, simply by contacting info@pharmaeducationcenter.it. It is asked to notify the participant replacement request within 5 days before the starting date of the event, specifying the full name and surname of the enrolled participant as well as the full name and surname of the substitute.